Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma

Ixazomib is an investigational proteasome inhibitor that has shown preclinical activity in lymphoma models. This phase 1 study assessed the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics and preliminary activity of intravenous (IV) ixazomib in relapsed/refract...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Cancer J
Auteurs principaux: Assouline, S E, Chang, J, Cheson, B D, Rifkin, R, Hamburg, S, Reyes, R, Hui, A-M, Yu, J, Gupta, N, Di Bacco, A, Shou, Y, Martin, P
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2014
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4220649/
https://ncbi.nlm.nih.gov/pubmed/25325301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2014.71
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires